NASDAQ Global Market • Healthcare • Biotechnology • BE • USD
Celyad Oncology S.A. (CYAD) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 3 recommend buying, 2 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
